Metsera brings its portfolio of experimental obesity drugs, with MET-097i, a GLP-1 injectable, and MET-233i, which mimics the pancreatic hormone amylin, being the key among them. MET-233i is being ...
(Reuters) -Pfizer said on Monday it would acquire drug developer Metsera in a deal valued at up to $7.3 billion, including future payments, as it seeks to gain a foothold in the fast-growing obesity ...
Germany’s performance rights organization, GEMA, plans to reduce its commission on all “on-demand music distribution” to 7% from 10% by 2027, a move that is expected to increase annual payouts to ...
Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook The exterior of CATL's headquarters in the eastern Chinese city of Ningde. Credit: CATL Chinese ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback